You are here

Novo Nordisk aims to be ahead of the pharma pack with Iran investment

Novo Nordisk has maintained a staff of some 130 in Iran through the sanctions era and it now plans to more than double that following a decision to invest 70 million euros on a factory in the country.


DANISH drugmaker Novo Nordisk, the world's top insulin supplier, expects to be ahead of the pack now nuclear sanctions are lifted in Iran, thanks to a continuous presence and a pre-emptive investment plan.

The country is an attractive target for Big Pharma seeking to sell new